Do analysts recommend VNDA or ZYBT?

Vanda Pharmaceuticals currently has a consensus price target of $13.70, indicating a potential upside of 158.98%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vanda Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, VNDA or ZYBT?

Zhengye Biotechnology has lower revenue, but higher earnings than Vanda Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vanda Pharmaceuticals $216.10M 1.48 -$220.47M -$4.63 N/A Zhengye Biotechnology $16.64M 4.93 -$9.98M N/A N/A

Does the media refer more to VNDA or ZYBT?

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 4 mentions for Vanda Pharmaceuticals and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.94 beat Vanda Pharmaceuticals' score of 0.85 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZYBT or AMRN?

Amarin has a consensus target price of $13.00, indicating a potential downside of 6.94%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33

Which has better valuation and earnings, ZYBT or AMRN?

Zhengye Biotechnology has higher earnings, but lower revenue than Amarin. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 4.93 -$9.98M N/A N/A Amarin $186.23M 1.58 -$38.80M -$0.99 N/A

Does the media refer more to ZYBT or AMRN?

In the previous week, Amarin had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 6 mentions for Amarin and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.94 beat Amarin's score of 0.52 indicating that Zhengye Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZYBT or NMRA?

Neumora Therapeutics has a consensus target price of $6.57, indicating a potential upside of 372.76%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Neumora Therapeutics 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has preferable earnings and valuation, ZYBT or NMRA?

Zhengye Biotechnology has higher revenue and earnings than Neumora Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 4.93 -$9.98M N/A N/A Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A

Is ZYBT or NMRA more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Neumora Therapeutics N/A -242.28% -131.32%

Does the media prefer ZYBT or NMRA?

In the previous week, Neumora Therapeutics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 4 mentions for Neumora Therapeutics and 2 mentions for Zhengye Biotechnology. Neumora Therapeutics' average media sentiment score of 1.25 beat Zhengye Biotechnology's score of 0.94 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ZYBT or TTRX?

Turn Therapeutics has a consensus target price of $8.00, suggesting a potential downside of 18.70%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Turn Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, ZYBT or TTRX?

Turn Therapeutics has lower revenue, but higher earnings than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 4.93 -$9.98M N/A N/A Turn Therapeutics N/A N/A -$3.19M -$0.29 N/A

Is ZYBT or TTRX more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Turn Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Turn Therapeutics N/A -230.84% -53.19%

Does the media refer more to ZYBT or TTRX?

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 2 articles in the media. Turn Therapeutics' average media sentiment score of 1.83 beat Zhengye Biotechnology's score of 0.94 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, ZNTL or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Zentalis Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zentalis Pharmaceuticals N/A N/A -$137.06M -$1.95 N/A Zhengye Biotechnology $16.64M 4.93 -$9.98M N/A N/A

Is ZNTL or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Zhengye Biotechnology N/A N/A N/A

Does the media refer more to ZNTL or ZYBT?

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Zentalis Pharmaceuticals and 2 mentions for Zhengye Biotechnology. Zentalis Pharmaceuticals' average media sentiment score of 1.76 beat Zhengye Biotechnology's score of 0.94 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Zhengye Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zhengye Biotechnology (ZYBT) Competitors

$1.73 -0.03 (-1.70%)

As of 08/28/2026 04:00 PM Eastern

Compare

ZYBT vs. VNDA, AMRN, NMRA, TTRX, and ZNTL

Should you buy Zhengye Biotechnology stock or one of its competitors? Zhengye Biotechnology's main competitors and comparable companies include Vanda Pharmaceuticals (VNDA), Amarin (AMRN), Neumora Therapeutics (NMRA), Turn Therapeutics (TTRX), and Zentalis Pharmaceuticals (ZNTL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zhengye Biotechnology compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

Zhengye Biotechnology has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Zhengye Biotechnology's return on equity of 0.00% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
Zhengye Biotechnology	N/A	N/A	N/A

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Vanda Pharmaceuticals had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 4 mentions for Vanda Pharmaceuticals and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.94 beat Vanda Pharmaceuticals' score of 0.85 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vanda Pharmaceuticals currently has a consensus price target of $13.70, indicating a potential upside of 158.98%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Vanda Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zhengye Biotechnology has lower revenue, but higher earnings than Vanda Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.48	-$220.47M	-$4.63	N/A
Zhengye Biotechnology	$16.64M	4.93	-$9.98M	N/A	N/A

Vanda Pharmaceuticals has a beta of 0.64, suggesting that its stock price is 36% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.72, suggesting that its stock price is 372% less volatile than the broader market.

Summary

Vanda Pharmaceuticals beats Zhengye Biotechnology on 8 of the 14 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Amarin?

Zhengye Biotechnology (NASDAQ:ZYBT) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Amarin had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 6 mentions for Amarin and 2 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.94 beat Amarin's score of 0.52 indicating that Zhengye Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zhengye Biotechnology has a beta of -2.72, indicating that its share price is 372% less volatile than the broader market. Comparatively, Amarin has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Zhengye Biotechnology has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Zhengye Biotechnology's return on equity of 0.00% beat Amarin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Amarin	-14.56%	-0.20%	-0.14%

Amarin has a consensus target price of $13.00, indicating a potential downside of 6.94%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

22.3% of Amarin shares are held by institutional investors. 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zhengye Biotechnology has higher earnings, but lower revenue than Amarin.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	4.93	-$9.98M	N/A	N/A
Amarin	$186.23M	1.58	-$38.80M	-$0.99	N/A

Summary

Amarin beats Zhengye Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Neumora Therapeutics?

Zhengye Biotechnology (NASDAQ:ZYBT) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

In the previous week, Neumora Therapeutics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 4 mentions for Neumora Therapeutics and 2 mentions for Zhengye Biotechnology. Neumora Therapeutics' average media sentiment score of 1.25 beat Zhengye Biotechnology's score of 0.94 indicating that Neumora Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neumora Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neumora Therapeutics has a consensus target price of $6.57, indicating a potential upside of 372.76%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Neumora Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Zhengye Biotechnology's return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Neumora Therapeutics	N/A	-242.28%	-131.32%

Zhengye Biotechnology has a beta of -2.72, indicating that its share price is 372% less volatile than the broader market. Comparatively, Neumora Therapeutics has a beta of 2.75, indicating that its share price is 175% more volatile than the broader market.

Zhengye Biotechnology has higher revenue and earnings than Neumora Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	4.93	-$9.98M	N/A	N/A
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A

47.7% of Neumora Therapeutics shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Neumora Therapeutics beats Zhengye Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Turn Therapeutics?

Zhengye Biotechnology (NASDAQ:ZYBT) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Turn Therapeutics has lower revenue, but higher earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	4.93	-$9.98M	N/A	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

In the previous week, Zhengye Biotechnology and Zhengye Biotechnology both had 2 articles in the media. Turn Therapeutics' average media sentiment score of 1.83 beat Zhengye Biotechnology's score of 0.94 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Zhengye Biotechnology's return on equity of 0.00% beat Turn Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Turn Therapeutics	N/A	-230.84%	-53.19%

Turn Therapeutics has a consensus target price of $8.00, suggesting a potential downside of 18.70%. Given Turn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Turn Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Turn Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Turn Therapeutics beats Zhengye Biotechnology on 6 of the 9 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Zentalis Pharmaceuticals currently has a consensus target price of $6.75, suggesting a potential upside of 77.63%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Zentalis Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Zentalis Pharmaceuticals had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 5 mentions for Zentalis Pharmaceuticals and 2 mentions for Zhengye Biotechnology. Zentalis Pharmaceuticals' average media sentiment score of 1.76 beat Zhengye Biotechnology's score of 0.94 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Zhengye Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Zentalis Pharmaceuticals has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.72, meaning that its share price is 372% less volatile than the broader market.

Zhengye Biotechnology has higher revenue and earnings than Zentalis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	N/A	N/A	-$137.06M	-$1.95	N/A
Zhengye Biotechnology	$16.64M	4.93	-$9.98M	N/A	N/A

Zhengye Biotechnology's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

Zentalis Pharmaceuticals beats Zhengye Biotechnology on 6 of the 10 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYBT vs. The Competition

Export

Metric	Zhengye Biotechnology	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$81.99M	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	N/A	787.65	273.16	25.45
Price / Sales	4.93	789.00	640.19	89.89
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	1.86	11.97	12.98	6.14
Net Income	-$9.98M	$2.83B	$3.48B	$348.86M
7 Day Performance	-15.20%	0.39%	0.13%	-0.80%
1 Month Performance	27.21%	5.34%	7.08%	4.13%
1 Year Performance	-81.52%	6.05%	24.67%	15.17%

Zhengye Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYBT Zhengye Biotechnology	0.3166 of 5 stars	$1.73 -1.7%	N/A	-81.5%	$81.99M	$16.64M	N/A	278	News Coverage Gap Up
VNDA Vanda Pharmaceuticals	2.4666 of 5 stars	$5.44 +1.7%	$13.70 +151.8%	+11.8%	$323.48M	$216.10M	N/A	290
AMRN Amarin	0.8974 of 5 stars	$14.07 -2.2%	$13.00 -7.6%	-7.1%	$303.64M	$213.65M	N/A	360	News Coverage
NMRA Neumora Therapeutics	2.9078 of 5 stars	$1.48 -5.1%	$6.57 +344.0%	-19.7%	$293.12M	N/A	N/A	108	Gap Down
TTRX Turn Therapeutics	1.8923 of 5 stars	$10.11 +5.0%	$8.00 -20.9%	N/A	$286.86M	N/A	N/A	2	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYBT) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. VNDA, AMRN, NMRA, TTRX, and ZNTL

How does Zhengye Biotechnology compare to Vanda Pharmaceuticals?

Summary

How does Zhengye Biotechnology compare to Amarin?

Summary

How does Zhengye Biotechnology compare to Neumora Therapeutics?

Summary

How does Zhengye Biotechnology compare to Turn Therapeutics?

Summary

How does Zhengye Biotechnology compare to Zentalis Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. VNDA, AMRN, NMRA, TTRX, and ZNTL

How does Zhengye Biotechnology compare to Vanda Pharmaceuticals?

Is VNDA or ZYBT more profitable?

Do institutionals and insiders believe in VNDA or ZYBT?

Does the media refer more to VNDA or ZYBT?

Do analysts recommend VNDA or ZYBT?

Which has preferable earnings & valuation, VNDA or ZYBT?

Which has more risk & volatility, VNDA or ZYBT?

Summary

How does Zhengye Biotechnology compare to Amarin?

Does the media refer more to ZYBT or AMRN?

Which has more volatility & risk, ZYBT or AMRN?

Is ZYBT or AMRN more profitable?

Do analysts rate ZYBT or AMRN?

Do insiders & institutionals believe in ZYBT or AMRN?

Which has better valuation and earnings, ZYBT or AMRN?

Summary

How does Zhengye Biotechnology compare to Neumora Therapeutics?

Does the media prefer ZYBT or NMRA?

Do analysts rate ZYBT or NMRA?

Is ZYBT or NMRA more profitable?

Which has more volatility and risk, ZYBT or NMRA?

Which has preferable earnings and valuation, ZYBT or NMRA?

Do institutionals and insiders believe in ZYBT or NMRA?

Summary

How does Zhengye Biotechnology compare to Turn Therapeutics?

Which has stronger earnings & valuation, ZYBT or TTRX?

Does the media refer more to ZYBT or TTRX?

Is ZYBT or TTRX more profitable?

Do analysts rate ZYBT or TTRX?

Summary

How does Zhengye Biotechnology compare to Zentalis Pharmaceuticals?

Do analysts prefer ZNTL or ZYBT?

Does the media refer more to ZNTL or ZYBT?

Which has more volatility and risk, ZNTL or ZYBT?

Which has better valuation & earnings, ZNTL or ZYBT?

Is ZNTL or ZYBT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools